Research Article
The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective
Table 1
Utility values and selected costs.
| Input | Value |
| Health state utility values | | Progression-free | 0.745 | Progressed | 0.678 |
| Drug therapy costs (per cycle) | | Lenvatinib | $2,142 | Sorafenib | $4,320 |
| Medical resource use costs (per cycle) | | Physician visits (progression-free) | $176 | Physician visits (progressed) | $187 | Laboratory tests (progression-free) | $29 | Laboratory tests (progressed) | $23 | Radiological tests (progression-free) | $131 | Radiological tests (progressed) | $79 | Hospitalisation (progression-free) | $27 | Hospitalisation (progressed) | $80 |
| Adverse event management costs (per event) | | Aspartate aminotransferase increased | $443 | Asthenia | $1,879 | Blood bilirubin increased | $1,954 | Diarrhea | $384 | Fatigue | $452 | Gamma-glutamyl transferase increased | $418 | Hypertension | $482 | Palmar-plantar erythrodysesthesia | $418 | Platelet count decreased | $418 | Proteinuria | $418 | Weight decreased | $1,845 |
| Other costs | | Mortality cost (applied at time of death) | $31,583 |
|
|